Pfizer and Bayer in deal for pipeline diabetes, obesity treatments

Pfizer and Bayer have entered an agreement granting Pfizer worldwide rights to Bayer’s pipeline DGAT-1 inhibitor treatments for obesity and diabetes. Both companies agreed that Bayer would receive an upfront fee, milestone payments and royalties on sales of any compounds that successfully make it to market. Financial terms of the deal were not disclosed. The deal is expected to close in the second half of 2006. The lead compound in the class, BAY 74-4113, is a potential treatment for Type 2 diabetes and obesity currently in Phase I of clinical development.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.